Premium
Maxillary Sinus Augmentation With Recombinant Human Bone Morphogenetic Protein‐2 and Particulate Allograft Without an Absorbable Sponge: A Case Report
Author(s) -
Barnett Andrew S.,
Soardi Carlo Maria,
Wang HomLay
Publication year - 2014
Publication title -
clinical advances in periodontics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.182
H-Index - 2
eISSN - 2163-0097
pISSN - 2573-8046
DOI - 10.1902/cap.2013.130017
Subject(s) - medicine , bone morphogenetic protein , maxillary sinus , sinus (botany) , sinus lift , surgery , implant , osteoplasty , dentistry , resorption , bone morphogenetic protein 2 , human bone , pathology , biochemistry , chemistry , botany , biology , in vitro , gene , genus
Introduction: Recently, biologic agents have been added to bone graft materials in sinus‐augmentation surgeries to accelerate the rate of regeneration. One such agent is recombinant human bone morphogenetic protein‐2 (rhBMP‐2) using an absorbable collagen sponge (ACS) as a carrier. Researchers have previously shown that, not only can rhBMP‐2 be successfully added to an allograft, but that the amount of ACS used is directly related to an increase in future graft shrinkage. There are limited data on adding rhBMP‐2 to an allograft mixture without any ACS. Hence, the objective of this case report is to provide the first histomorphometric analysis using rhBMP‐2 with allograft mixture without an ACS in an effort to reduce graft shrinkage. Case Presentation: A patient presented requiring implants in the right posterior, but maxillary sinus pneumatization and ridge resorption resulted in inadequate bone height. A sinus‐augmentation procedure was completed using rhBMP‐2 with allograft mixture without an ACS in an effort to reduce graft shrinkage; bone core biopsies were trephined at implant placement 6 months later and underwent histologic analysis. The graft regenerated as viable, mature, mineralized bone, and implant placement was successful. Conclusions: To the best of the authors’ knowledge, this is the first report indicating that directly adding rhBMP‐2 to an allograft mixture without an ACS carrier is a viable supplementation to a sinus‐augmentation procedure. However, long‐term randomized controlled trials are needed for proper quantitative analysis and to determine its long‐term predictability and efficacy.